A Checklist Approach for Enhanced Outpatient Guideline-Directed Management in the Secondary Prevention of Atherosclerotic Cardiovascular Disease

Taha, Mohamad; Avenatti, Eleonora; Li, Daniel S; Ohonba, Tirhas; Cainzos‐Achirica, Miguel; Patel, Kershaw V.; Nasir, Khurram

doi:10.14797/mdcvj.907

Cited by 3 publications

(2 citation statements)

References 37 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A highly effective strategy to bridge the gap between emerging evidence and clinical practice includes checklist methods for ASCVD prevention. 81 Importantly, utilization of PCMCs can aid in overcoming therapeutic inertia in the use of screening tests such as CAC, which allows for better screening, early identification of at-risk patients, reclassification, and adequate resource allocation. 82 This is particularly useful for women, who are often perceived as having a lower CVD risk compared with men.…”

Section: Systemic and Community-level Strategies Establishing Special...mentioning

confidence: 99%

Primary Prevention of Cardiovascular Disease in Women

Shahid,

Avenatti,

Titus

et al. 2024

Methodist DeBakey Cardiovascular Journal

Self Cite

View full text Add to dashboard Cite

Cardiovascular disease (CVD) remains a leading cause of mortality in women, necessitating innovative primary prevention strategies. Contemporary guidelines on primary prevention of CVD highlight the increasing prevalence of CVD risk factors and emphasize the significance of female-specific risk enhancers that substantially augment the future risk of CVD. These risk factors occur throughout a woman's life cycle, such as hormonal contraception, hypertensive disorders of pregnancy, and menopause, all of which confer an added layer of risk in women beyond the conventional risk factors. Despite this, current methods may not fully capture the nuanced vulnerabilities in women that increase their risk of CVD. In this review, we highlight gender-specific risk enhancers and subsequent prevention as well as strategies to improve primary prevention of CVD in women.

show abstract

Section: Systemic and Community-level Strategies Establishing Special...mentioning

confidence: 99%

Primary Prevention of Cardiovascular Disease in Women

Shahid,

Avenatti,

Titus

et al. 2024

Methodist DeBakey Cardiovascular Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, we have also proposed a framework using comprehensive checklists or established bundles to optimize patients to reduce existing gaps in LLT intensification gaps as well as encourage prompt adoption of evidence-based practice in managing high-risk patients. 9 As shown with these examples, there is no one size to fit all. To overcome local hurdles in addressing these gaps, flexibility with a multipronged strategy best suited for each health system would be required.…”

mentioning

confidence: 97%

Therapeutic Inertia in Lipid-Lowering Treatment Intensification: Digital Tools and Performance Management to the Rescue?

Nasir

Salami

2022

Circ: Cardiovascular Quality and Outcomes

Self Cite

View full text Add to dashboard Cite

Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum

Lepor

Michos

2023

JAHA

View full text Add to dashboard Cite

Management of elevated low‐density lipoprotein cholesterol (LDL‐C) is central to preventing atherosclerotic cardiovascular disease (ASCVD) and key to reducing the risk of ASCVD events. Current guidelines on the management of blood cholesterol recommend statins as first‐line therapy for LDL‐C reduction according to an individual's ASCVD risk and baseline LDL‐C levels. The addition of nonstatin lipid‐lowering therapy to statins to achieve intensive LDL‐C lowering is recommended for patients at very high risk of ASCVD events, including patients with familial hypercholesterolemia who have not achieved adequate LDL‐C lowering with statins alone. Despite guideline recommendations and clinical trial evidence to support the use of lipid‐lowering therapies for ASCVD risk reduction, most patients at high or very high risk do not meet LDL‐C thresholds. This review explores the challenges associated with LDL‐C lowering in contemporary clinical practice and proposes a framework for rethinking the binary definition of ASCVD, shifting from “primary” versus “secondary” prevention to a “continuum of risk.” The approach considers the role of plaque burden and progression in subclinical disease and emphasizes the importance of early risk assessment and treatment for preventing first cardiovascular events. Patients at high risk of ASCVD events who require significant LDL‐C lowering should be considered for combination therapies comprising statin and nonstatin agents. Practical guidance for the pharmacological management of elevated LDL‐C, both now and in the future, is provided.

show abstract

A Checklist Approach for Enhanced Outpatient Guideline-Directed Management in the Secondary Prevention of Atherosclerotic Cardiovascular Disease

Cited by 3 publications

References 37 publications

Primary Prevention of Cardiovascular Disease in Women

Primary Prevention of Cardiovascular Disease in Women

Therapeutic Inertia in Lipid-Lowering Treatment Intensification: Digital Tools and Performance Management to the Rescue?

Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum

Contact Info

Product

Resources

About